RNA Formulation Videos

1. In What Ways Are We Underestimating LNP Complexity Today? 12/4/2024

   As the RNA-LNP space continues to diversify beyond linear mRNA and infectious disease vaccines, Kate Zhang of Hopewell Therapeutics, Sumit Luthra of Sanofi, and Ben Muir of BioNTech each address several misconceptions about LNP composition today and how the rise of novel RNA modalities, more advanced mechanisms of action, and novel lipids are challenging our understanding of/work with LNPs today.

2. Durable Liquid Nanoparticle (LNP) Systems 12/6/2024

   Discover the benefits of an LNP system that offers unparalleled durability and sustainability. Eliminate wear parts, plastic waste, and running costs with a system designed for long-term performance and minimal environmental impact.

3. Advancements In LNP CMC: What Are The Current "Known Knowns"? 12/4/2024

   In this Advancing RNA Live clip, Sanofi’s Sumit Luthra highlights the learnings we’ve made to-date about how our processes — both in terms of unit operations and process conditions — inform our LNP composition/heterogeneity.

4. DNA Vaccine Development In A Global Pandemic: A Personal Account 4/14/2022

   Dr. Gerrit Borchard, University of Geneva, presents a personal account of DNA vaccine development in a global pandemic.

5. Addressing Industry Challenges In mRNA Product Commercialization

   While the speed of production and flexibility of mRNA are appealing, several industry challenges must still be addressed to realize the full potential and further expand its use.

6. Scale Up And Manufacturing Of RNA-LNPs For A COVID-19 Vaccine 4/13/2022

   Dr. Jason Coleman, Clinical Application Scientist Lead with Precision NanoSystems, presents on an overview of the development and scale-up activities needed to progress this saRNA vaccine to the clinic.

7. RNA-LNP Manufacturing Technology Delivering Transformative Medicines 10/13/2022

   NxGen™ microfluidic technology enables controlled and precise assembly of high-quality, uniform LNPs, ensuring reproducible scale-up of RNA-LNPs while maximizing drug loading and particle quality.

8. Translation Of RNA Nanomedicines From Design To Clinical 4/14/2022

   mRNA therapeutics are applicable to cancer immunotherapies, infectious diseases, and other indications that require protein replacement therapy or antibodies.

9. Strategies For Scaling Up mRNA Manufacturing 4/11/2022

   The clinical promise of mRNA therapeutics and vaccines is clear, but compared to monoclonal antibodies or viral vectors, their novelty also brings new challenges to the manufacturing process.

10. Nanoforming Biologics, GLP-1s: From I.V. To Sub Q And Inhaled Delivery 9/9/2025

    Developing new delivery routes is essential for creating more effective treatments. Nanoforming enables new routes to simplify dosing, enhance patient comfort, and reduce healthcare costs.